{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:07:24Z","timestamp":1790330844102,"version":"4.1.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013318","name":"Shanxi Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["202403021221275"],"award-info":[{"award-number":["202403021221275"]}],"id":[{"id":"10.13039\/501100013318","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013318","name":"Shanxi Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["202403021221265"],"award-info":[{"award-number":["202403021221265"]}],"id":[{"id":"10.13039\/501100013318","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020209","name":"Shaanxi Provincial Health Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020209","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018684","name":"National Health Commission of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018684","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017949","name":"Health Commission of Shanxi Province","doi-asserted-by":"publisher","award":["2025ZD012"],"award-info":[{"award-number":["2025ZD012"]}],"id":[{"id":"10.13039\/100017949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017949","name":"Health Commission of Shanxi Province","doi-asserted-by":"publisher","award":["2021114"],"award-info":[{"award-number":["2021114"]}],"id":[{"id":"10.13039\/100017949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013794","name":"Shanxi Provincial Education Department","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bcp.2026.118495","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:52:34Z","timestamp":1790175154000},"page":"118495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["GLP-1 receptor agonists and podocyte senescence in diabetic kidney disease: structural pharmacology, mechanistic evidence, and multi-receptor agonism"],"prefix":"10.1016","volume":"254","author":[{"given":"Hongyu","family":"Yue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaozong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhicheng","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongyang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baodong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bcp.2026.118495_b0005","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2174\/0929867330666230621112215","article-title":"Aging and diabetic kidney disease: emerging pathogenetic mechanisms and clinical implications","volume":"31","author":"Chen","year":"2024","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.118495_b0010","doi-asserted-by":"crossref","DOI":"10.1002\/cph4.70003","article-title":"Type 2 diabetes mellitus: a comprehensive review of pathophysiology, comorbidities, and emerging therapies","volume":"15","author":"Singh","year":"2025","journal-title":"Compr. Physiol."},{"issue":"18","key":"10.1016\/j.bcp.2026.118495_b0015","doi-asserted-by":"crossref","first-page":"10882","DOI":"10.3390\/ijms231810882","article-title":"Recent advances in the emerging therapeutic strategies for diabetic kidney diseases","volume":"23","author":"Huang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118495_b0020","doi-asserted-by":"crossref","unstructured":"S. Shetty, R. Suvarna, A. Awasthi, M.V. Bhojaraja, J.M. Pappachan, Emerging Biomarkers and Innovative Therapeutic Strategies in Diabetic Kidney Disease: A Pathway to Precision Medicine, Diagnostics (Basel, Switzerland) 15(8) (2025) 973.","DOI":"10.3390\/diagnostics15080973"},{"key":"10.1016\/j.bcp.2026.118495_b0025","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/978-3-319-55330-6_29","article-title":"Prohibitin signaling at the kidney filtration barrier","volume":"982","author":"Ising","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118495_b0030","doi-asserted-by":"crossref","first-page":"F644","DOI":"10.1152\/ajprenal.00417.2023","article-title":"Podocytes from hypertensive and obese mice acquire an inflammatory, senescent, and aged phenotype","volume":"326","author":"McKinzie","year":"2024","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"12","key":"10.1016\/j.bcp.2026.118495_b0035","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.34067\/KID.0000000000000284","article-title":"Podocyte senescence and aging","volume":"4","author":"Shankland","year":"2023","journal-title":"Kidney360"},{"issue":"2","key":"10.1016\/j.bcp.2026.118495_b0040","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.118495_b0045","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00592-023-02184-y","article-title":"GLP-1RAs inhibit the activation of the NLRP3 inflammasome signaling pathway to regulate mouse renal podocyte pyroptosis","volume":"61","author":"Li","year":"2024","journal-title":"Acta Diabetol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118495_b0050","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tips.2025.03.003","article-title":"Structural pharmacology and mechanisms of GLP-1R signaling","volume":"46","author":"Zhou","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118495_b0055","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/s41467-020-14934-5","article-title":"Full-length human GLP-1 receptor structure without orthosteric ligands","volume":"11","author":"Wu","year":"2020","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.bcp.2026.118495_b0060","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.molcel.2020.09.020","article-title":"Differential GLP-1R binding and activation by peptide and non-peptide agonists","volume":"80","author":"Zhang","year":"2020","journal-title":"Mol. Cell"},{"issue":"2","key":"10.1016\/j.bcp.2026.118495_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109374","article-title":"Structure and dynamics of semaglutide- and taspoglutide-bound GLP-1R-Gs complexes","volume":"36","author":"Zhang","year":"2021","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.bcp.2026.118495_b0070","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"issue":"10","key":"10.1016\/j.bcp.2026.118495_b0075","doi-asserted-by":"crossref","DOI":"10.1530\/EC-23-0284","article-title":"Protective effect of GLP-1 analog liraglutide on podocytes in mice with diabetic nephropathy","volume":"12","author":"Shi","year":"2023","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.bcp.2026.118495_b0080","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.bbrc.2023.04.012","article-title":"GLP-1 receptor agonist, liraglutide, protects podocytes from apoptosis in diabetic nephropathy by promoting white fat browning","volume":"664","author":"Wang","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2026.118495_b0085","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.kint.2023.09.029","article-title":"Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation","volume":"105","author":"Sourris","year":"2024","journal-title":"Kidney Int."},{"issue":"3","key":"10.1016\/j.bcp.2026.118495_b0090","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.apsb.2026.01.023","article-title":"Distinctive molecular architectures of G(q)- and G(i)-coupled GLP-1 receptors","volume":"16","author":"Zhou","year":"2026","journal-title":"Acta Pharm. Sin. B"},{"issue":"7694","key":"10.1016\/j.bcp.2026.118495_b0095","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nature25773","article-title":"Phase-plate cryo-EM structure of a biased agonist-bound human GLP-1 receptor-Gs complex","volume":"555","author":"Liang","year":"2018","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.bcp.2026.118495_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2026.117718","article-title":"N-terminally modified GLP1R agonists drive G protein bias via extracellular loop 3 displacement","volume":"45","author":"Zhao","year":"2026","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.bcp.2026.118495_b0105","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/s41467-018-03941-2","article-title":"Targeting GLP-1 receptor trafficking to improve agonist efficacy","volume":"9","author":"Jones","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118495_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116119","article-title":"The role of G protein-coupled receptor kinases in GLP-1R \u03b2-arrestin recruitment and internalisation","volume":"222","author":"McNeill","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118495_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.100991","article-title":"Disconnect between signalling potency and invivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists","volume":"37","author":"Lucey","year":"2020","journal-title":"Mol. Metab."},{"issue":"17","key":"10.1016\/j.bcp.2026.118495_b0120","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"issue":"8","key":"10.1016\/j.bcp.2026.118495_b0125","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11892-020-01314-y","article-title":"Role of senescent renal cells in pathophysiology of diabetic kidney disease","volume":"20","author":"Wiley","year":"2020","journal-title":"Curr. Diab. Rep."},{"issue":"2","key":"10.1016\/j.bcp.2026.118495_b0130","doi-asserted-by":"crossref","DOI":"10.1080\/0886022X.2024.2398712","article-title":"Podocyte senescence: from molecular mechanisms to therapeutics","volume":"46","author":"Zhao","year":"2024","journal-title":"Ren. Fail."},{"issue":"1","key":"10.1016\/j.bcp.2026.118495_b0135","doi-asserted-by":"crossref","first-page":"F120","DOI":"10.1152\/ajprenal.00261.2023","article-title":"Podocyte injury at young age causes premature senescence and worsens glomerular aging, American journal of physiology","volume":"326","author":"Veloso Pereira","year":"2024","journal-title":"Ren. Physiol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118495_b0140","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.kint.2024.12.013","article-title":"G-protein coupled receptor GPR124 protects against podocyte senescence and injury in diabetic kidney disease","volume":"107","author":"Li","year":"2025","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.bcp.2026.118495_b0145","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13287-023-03354-z","article-title":"Intravenous injection of human umbilical cord-derived mesenchymal stem cells ameliorates not only blood glucose but also nephrotic complication of diabetic rats through autophagy-mediated anti-senescent mechanism","volume":"14","author":"Li","year":"2023","journal-title":"Stem Cell Res Ther"},{"issue":"5","key":"10.1016\/j.bcp.2026.118495_b0150","doi-asserted-by":"crossref","first-page":"F1563","DOI":"10.1152\/ajprenal.90302.2008","article-title":"Accelerated senescence in the kidneys of patients with type 2 diabetic nephropathy","volume":"295","author":"Verzola","year":"2008","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.bcp.2026.118495_b0155","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ebiom.2019.08.069","article-title":"Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease","volume":"47","author":"Hickson","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bcp.2026.118495_b0160","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.phrs.2018.03.004","article-title":"The glucagon-like peptide-1 (GLP-1) analog liraglutide attenuates renal fibrosis","volume":"131","author":"Li","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2026.118495_b0165","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.freeradbiomed.2021.05.025","article-title":"AGE\/RAGE in diabetic kidney disease and ageing kidney","volume":"171","author":"Wu","year":"2021","journal-title":"Free Radic. Biol. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.118495_b0170","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s13105-022-00939-9","article-title":"Liraglutide provides cardioprotection through the recovery of mitochondrial dysfunction and oxidative stress in aging hearts","volume":"79","author":"Durak","year":"2023","journal-title":"J. Physiol. Biochem."},{"key":"10.1016\/j.bcp.2026.118495_b0175","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3389\/fphar.2020.00805","article-title":"Stimulation of GLP-1 receptor inhibits methylglyoxal-induced mitochondrial dysfunctions in H9c2 cardiomyoblasts: potential role of Epac\/PI3K\/Akt pathway","volume":"11","author":"Nuamnaichati","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118495_b0180","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12929-024-01025-6","article-title":"Attenuating mitochondrial dysfunction and morphological disruption with PT320 delays dopamine degeneration in MitoPark mice","volume":"31","author":"Wang","year":"2024","journal-title":"J. Biomed. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118495_b0185","doi-asserted-by":"crossref","first-page":"e1053","DOI":"10.1002\/iid3.1053","article-title":"Metformin inhibits high glucose-induced apoptosis of renal podocyte through regulating miR-34a\/SIRT1 axis","volume":"12","author":"Zhuang","year":"2024","journal-title":"Immun. Inflammation Dis."},{"key":"10.1016\/j.bcp.2026.118495_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.149713","article-title":"Podocyte Ercc1 is indispensable for glomerular integrity","volume":"704","author":"Hama","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.bcp.2026.118495_b0195","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1681\/ASN.2022050598","article-title":"Cell cycle and senescence regulation by podocyte histone deacetylase 1 and 2","volume":"34","author":"Medina Rangel","year":"2023","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.bcp.2026.118495_b0200","first-page":"886","article-title":"The impairment of endothelial autophagy accelerates renal senescence by ferroptosis and NLRP3 inflammasome signaling pathways with the disruption of endothelial barrier","volume":"13","author":"Kim","year":"2024","journal-title":"Antioxidants (Basel Switzerland)"},{"issue":"4","key":"10.1016\/j.bcp.2026.118495_b0205","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.kint.2020.12.012","article-title":"Low expression of HIV genes in podocytes accelerates the progression of diabetic kidney disease in mice","volume":"99","author":"Feng","year":"2021","journal-title":"Kidney Int."},{"issue":"3","key":"10.1016\/j.bcp.2026.118495_b0210","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.apsb.2023.11.020","article-title":"Design and discovery of a highly potent ultralong-acting GLP-1 and glucagon co-agonist for attenuating renal fibrosis","volume":"14","author":"Zhao","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"3","key":"10.1016\/j.bcp.2026.118495_b0215","doi-asserted-by":"crossref","first-page":"430","DOI":"10.2337\/dc24-1773","article-title":"Tirzepatide associated with reduced albuminuria in participants with type 2 diabetes: pooled post hoc analysis from the randomized active- and placebo-controlled SURPASS-1-5 clinical trials","volume":"48","author":"Apperloo","year":"2025","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.bcp.2026.118495_b0220","first-page":"774","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial, the lancet","volume":"10","author":"Heerspink","year":"2022","journal-title":"Diabet. Endocrinol."},{"issue":"7","key":"10.1016\/j.bcp.2026.118495_b0225","first-page":"544","article-title":"A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial, the lancet","volume":"14","author":"Zoungas","year":"2026","journal-title":"Diabet. Endocrinol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118495_b0230","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1016\/j.ekir.2025.03.049","article-title":"The effect of retatrutide on kidney parameters in participants with type 2 diabetes mellitus and\/or obesity","volume":"10","author":"Heerspink","year":"2025","journal-title":"Kid. Int. Rep."},{"issue":"7","key":"10.1016\/j.bcp.2026.118495_b0235","doi-asserted-by":"crossref","first-page":"F963","DOI":"10.1152\/ajprenal.00259.2012","article-title":"Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice","volume":"303","author":"Rieg","year":"2012","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118495_b0240","doi-asserted-by":"crossref","first-page":"F712","DOI":"10.1152\/ajprenal.00088.2024","article-title":"Glucagon receptor activation contributes to the development of kidney injury","volume":"327","author":"Bomholt","year":"2024","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118495_b0245","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cmet.2023.12.024","article-title":"Downregulation of the kidney glucagon receptor, essential for renal function and systemic homeostasis, contributes to chronic kidney disease","volume":"36","author":"Wang","year":"2024","journal-title":"Cell Metab."},{"issue":"6","key":"10.1016\/j.bcp.2026.118495_b0250","first-page":"1058","article-title":"Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease","volume":"41","author":"Heerspink","year":"2026","journal-title":"Nephrology"},{"issue":"1","key":"10.1016\/j.bcp.2026.118495_b0255","first-page":"15","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials, the lancet","volume":"13","author":"Badve","year":"2025","journal-title":"Diabet. Endocrinol."},{"issue":"9","key":"10.1016\/j.bcp.2026.118495_b0260","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.bcp.2026.118495_b0265","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118495_b0270","unstructured":"H.C. Gerstein, H.M. Colhoun, G.R. Dagenais, R. Diaz, M. Lakshmanan, P. Pais, J. Probstfield, F.T. Botros, M.C. Riddle, L. Ryd\u00e9n, D. Xavier, C.M. Atisso, L. Dyal, S. Hall, P. Rao-Melacini, G. Wong, A. Avezum, J. Basile, N. Chung, I. Conget, W.C. Cushman, E. Franek, N. Hancu, M. Hanefeld, S. Holt, P. Jansky, M. Keltai, F. Lanas, L.A. Leiter, P. Lopez-Jaramillo, E.G. Cardona Munoz, V. Pirags, N. Pogosova, P.J. Raubenheimer, J.E. Shaw, W.H. Sheu, T. Temelkova-Kurktschiev, Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial, Lancet (London, England) 394(10193) (2019) 131\u2013138."},{"issue":"10","key":"10.1016\/j.bcp.2026.118495_b0275","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","article-title":"Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial","volume":"30","author":"Mann","year":"2024","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.bcp.2026.118495_b0280","doi-asserted-by":"crossref","first-page":"841","DOI":"10.2215\/CJN.0000000974","article-title":"Kidney and Survival Outcomes with Semaglutide by CKD Severity in the FLOW Trial","volume":"21","author":"Tuttle","year":"2026","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"7","key":"10.1016\/j.bcp.2026.118495_b0285","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","article-title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","volume":"30","author":"Colhoun","year":"2024","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118495_b0290","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41591-024-03327-6","article-title":"Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial","volume":"31","author":"Apperloo","year":"2025","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.bcp.2026.118495_b0295","article-title":"Effects of oral semaglutide on kidney outcomes in people with type 2 diabetes: a nationwide, multicentre, retrospective, observational study (Renal_ENDO2S-RWD substudy)","volume":"18","author":"Moreno-P\u00e9rez","year":"2025","journal-title":"Clin. Kid. J."},{"issue":"4","key":"10.1016\/j.bcp.2026.118495_b0300","article-title":"Kidney outcomes with GLP-1 receptor agonists in people with type 2 diabetes already receiving SGLT2 inhibitors: a target trial emulation study using UK primary care data, the Lancet","volume":"2","author":"Jansz","year":"2026","journal-title":"Primary Care"},{"issue":"5","key":"10.1016\/j.bcp.2026.118495_b0305","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.70066","article-title":"Kidney outcomes with glucagon-like peptide-1 receptor agonists versus other glucose-lowering agents in people with type 2 diabetes: a systematic review and meta-analysis of real-world data","volume":"41","author":"Fishkin","year":"2025","journal-title":"Diabetes Metab. Res. Rev."},{"issue":"3","key":"10.1016\/j.bcp.2026.118495_b0310","doi-asserted-by":"crossref","first-page":"274","DOI":"10.23876\/j.krcp.23.109","article-title":"Urinary podocyte markers in diabetic kidney disease","volume":"43","author":"Li","year":"2024","journal-title":"Kid. Res. Clin. Pract."},{"issue":"14","key":"10.1016\/j.bcp.2026.118495_b0315","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.3390\/ijms26146662","article-title":"What a modern physician should know about microRNAs in the diagnosis and treatment of diabetic kidney disease","volume":"26","author":"Rodzo\u0144-Norwicz","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.bcp.2026.118495_b0320","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1681\/ASN.2013070763","article-title":"Urinary podocyte microparticles identify prealbuminuric diabetic glomerular injury","volume":"25","author":"Burger","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"21","key":"10.1016\/j.bcp.2026.118495_b0325","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.21037\/atm-20-441","article-title":"Diagnostic roles of urinary kidney microvesicles in diabetic nephropathy","volume":"8","author":"Cai","year":"2020","journal-title":"Ann. Transl. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118495_b0330","doi-asserted-by":"crossref","first-page":"18209","DOI":"10.1038\/s41598-020-75320-1","article-title":"Urinary podocyte mRNAs precede microalbuminuria as a progression risk marker in human type 2 diabetic nephropathy","volume":"10","author":"Fukuda","year":"2020","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.bcp.2026.118495_b0335","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.12669\/pjms.38.5.4719","article-title":"Effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on podocytes, inflammation, and oxidative stress in patients with diabetic nephropathy (DN)","volume":"38","author":"Liu","year":"2022","journal-title":"Pak. J. Med. Sci."},{"key":"10.1016\/j.bcp.2026.118495_b0340","doi-asserted-by":"crossref","DOI":"10.1177\/20543581241260948","article-title":"The Correlation of MicroRNA-21 with the nephrin, podocin, and urinary albumin-creatinine ratio in patients with type 2 diabetes and albuminuria: a cross-sectional study","volume":"11","author":"Nugroho","year":"2024","journal-title":"Can. J. Kidney Health Dis."},{"issue":"3","key":"10.1016\/j.bcp.2026.118495_b0345","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/jdi.12753","article-title":"Microribonucleic acid-192 as a specific biomarker for the early diagnosis of diabetic kidney disease","volume":"9","author":"Yang","year":"2018","journal-title":"J. Diabet. Investig."},{"key":"10.1016\/j.bcp.2026.118495_b0350","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/6789402","article-title":"The expression of miR-192 and its significance in diabetic nephropathy patients with different urine albumin creatinine ratio","volume":"2016","author":"Ma","year":"2016","journal-title":"J. Diabet. Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118495_b0355","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1681\/ASN.2020040487","article-title":"Association of multiple plasma biomarker concentrations with progression of prevalent diabetic kidney disease: findings from the chronic renal insufficiency cohort (CRIC) study","volume":"32","author":"Schrauben","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"issue":"7","key":"10.1016\/j.bcp.2026.118495_b0360","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12093","article-title":"Urinary extracellular vesicles: a position paper by the urine task force of the international society for extracellular vesicles","volume":"10","author":"Erdbr\u00fcgger","year":"2021","journal-title":"J. Extrac. Vesicles"},{"issue":"16","key":"10.1016\/j.bcp.2026.118495_b0365","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1016\/j.cell.2024.05.059","article-title":"Guidelines for minimal information on cellular senescence experimentation invivo","volume":"187","author":"Ogrodnik","year":"2024","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.bcp.2026.118495_b0370","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s40265-024-02090-9","article-title":"GLP-1 receptor agonists and SGLT2 Inhibitors in type 2 diabetes: pleiotropic cardiometabolic effects and add-on value of a combined therapy","volume":"84","author":"Scheen","year":"2024","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.bcp.2026.118495_b0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2024.101594","article-title":"Cardiovascular and renal effects of the combination therapy of a GLP-1 receptor agonist and an SGLT2 inhibitor in observational real-life studies","volume":"51","author":"Scheen","year":"2025","journal-title":"Diabetes Metab."},{"issue":"6","key":"10.1016\/j.bcp.2026.118495_b0380","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1172\/JCI72434","article-title":"Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect","volume":"124","author":"Sisley","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"30","key":"10.1016\/j.bcp.2026.118495_b0385","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb5460","article-title":"Epigenetic transcriptional reprogramming by WT1 mediates a repair response during podocyte injury","volume":"6","author":"Ettou","year":"2020","journal-title":"Sci. Adv."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226008373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226008373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:42:49Z","timestamp":1790329369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226008373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":77,"alternative-id":["S0006295226008373"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118495","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 receptor agonists and podocyte senescence in diabetic kidney disease: structural pharmacology, mechanistic evidence, and multi-receptor agonism","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118495","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118495"}}